Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
A monoclonal thyroid-stimulating antibody
Takao Ando, … , Yuji Nagayama, Terry F. Davies
Takao Ando, … , Yuji Nagayama, Terry F. Davies
Published December 1, 2002
Citation Information: J Clin Invest. 2002;110(11):1667-1674. https://doi.org/10.1172/JCI16991.
View: Text | PDF
Article Autoimmunity

A monoclonal thyroid-stimulating antibody

  • Text
  • PDF
Abstract

Research Article

Authors

Takao Ando, Rauf Latif, Alla Pritsker, Thomas Moran, Yuji Nagayama, Terry F. Davies

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
TSHR cleavage is not induced by MS-1. CHO-hTSHR cells were treated with ...
TSHR cleavage is not induced by MS-1. CHO-hTSHR cells were treated with 100 μU/ml of TSH for 24 hours and stained with two monoclonal TSHR-Ab’s, and showed a reduction in the immunoreactivity of RSR-4 (a) but not RSR-1 (b). In contrast, similar treatment with MS-1 (5 μg/ml) did not alter immunoreactivity by either RSR-4 (c) or RSR-1 (d), indicating that MS-1 did not accelerate TSHR cleavage. The thin lines indicate staining of CHO-hTSHR cells without TSH (a and b) or MS-1 (c and d), and thick lines indicate CHO-hTSHR cells with TSH (a and b) and MS-1 (c and d), respectively.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts